Summary
167 patients suffering from acute myocardial infarction (AMI) were recruited from 12 cardiology centres and given thrombolytic treatment. Cost—utility analyses were performed and a cost—utility ratio was computed according to time of initiation of thrombolysis after the AMI and the location of the infarct. Early thrombolysis (< 3 hours) proved to cost about the same per QALY ($US3734 vs $US3577) as late thrombolysis (> 3 hours), although posterior infarcts cost slightly more per QALY ($3433 vs $2996) than anterior infarcts. Quality of life coefficients for all patients after the AMI were judged to be about 40% less than before the AMI. Thus, in terms of resources consumed and patient well—being, time of treatment initiation or location of the infarct were less significant than the fact of having an AMI. In terms of quality of life, the best strategy is that which seeks to prevent AMI occurring.
Similar content being viewed by others
References
AIMS. The APSAC Intervention Mortality Study. Effects of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo—controlled clinical trial. Lancet 1: 545–549, 1988
Castiel D. L’analyse coût—avantage: critère de choix des investissements médicaux et stratègies thérapeutiques? Application à la thrombolyse précoce dans la prise en charge des malades coronariens. Thèse pour Ie Doctorat ès Sciences Economiques, Universite Paris XII, Créteil, 1991
Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes, Chapter 6, pp. 112–148, Oxford University Press, Oxford, 1987
Ganiats T, Schneidermann L. Principles of cost—effectiveness research. Journal of Family Practice 27: 77–84, 1988
Fletcher AE, Bulpitt CJ. Pharmacoeconomic evaluation of risk factors for cardiovascular disease: an epidemiological perspective. PharmacoEconomics 1: 33–44, 1992
GISSI. Gruppo Italiano per Ie studio della streptokinase nell’infarcto miocardico. Long term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet 2: 871–874, 1987
Hervé C, Castiel D, Gaillard M, Daussac C, Leroux V. Implications socioeconomiques de la pratique de la thrombolyse a la phase aigue de l’infarctus du myocarde. Archives des Maladies du Coeur et des Vaisseaux 82: 353–358, 1989
Hervé C, Castiel D, Gaillard M, Boisvert R, Leroux V. Costbenefit analysis of thrombolytic therapy. European Heart Journal 11: 1006–1010, 1990
Hervé C, Castiel D, Gaillard M, Leroux V. Methode d’evaluation de la qualite de vie apres infarctus du myocarde. Presse Medicale 20: 1623, 1991
ISIS 2. Second Internationa Study of Infarct Survival. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction. Lancet 2: 349–360, 1988
Li M. A logit model of homeownership. Econometrica 7: 1081–1096, 1977
Maddala GS. Econometrics, Chapter 9: Dummy variables and nonlinearities in multiole regression, pp. 163–171, McGrawHill, Singapore, 1987
Pell S, Fayerweather W. Trends in the incidence of myocardial infarction, and in associated mortality and morbidity in a large employed population, 1957–1983. New England Journal of Medicine 312: 1005–1011, 1985
Stason WB. Costs and benefits of risk factor reduction for coronary heart disease: insights from screening and treatment of serum cholesterol. American Heart Journal 119: 718–724, 1990
Vermeer F, Maarten L, Simoons M, de Zwoon C, van Es GA, et al. Cost—benefit analysis of early thrombolytic treatment with intracoronary streptokinase. British Heart Journal 59: 527–534, 1988
Weinstein MC, Stason WB. Foundations of cost—effectiveness analysis for health and medical practices. New England Journal of Medicine 296: 716–721, 1977
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Castiel, D., Hervé, C., Gaillard, M. et al. Cost—Utility Analysis of Early Thrombolytic Therapy. Pharmacoeconomics 1, 438–442 (1992). https://doi.org/10.2165/00019053-199201060-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199201060-00004